Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Mayo Clinic
City of Hope Medical Center
Indapta Therapeutics, INC.
University of Maryland, Baltimore
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Allogene Therapeutics
Roswell Park Cancer Institute
Shanxi Province Cancer Hospital
Oncotherapeutics
European Myeloma Network B.V.
Icahn School of Medicine at Mount Sinai
University of Athens
Mayo Clinic
Henan Cancer Hospital
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
University of Washington
University of Leeds
H. Lee Moffitt Cancer Center and Research Institute
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
UMC Utrecht
King's College Hospital NHS Trust
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.
University of Kentucky